Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 22.91
- Piotroski Score 2.00
- Grade Outperform
- Symbol (IDYA)
- Company IDEAYA Biosciences, Inc.
- Price $26.92
- Changes Percentage (1.2%)
- Change $0.32
- Day Low $26.30
- Day High $27.50
- Year High $47.74
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/18/2025
- Fiscal Year End N/A
- Average Stock Price Target $51.50
- High Stock Price Target $66.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.00
- Trailing P/E Ratio -19
- Forward P/E Ratio -19
- P/E Growth -19
- Net Income $-112,961,000
Income Statement
Quarterly
Annual
Latest News of IDYA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
'Vicky Vidya Ka Woh Wala Video' Scores $6 Million In 12 Days
Vicky Vidya Ka Woh Wala Video, a Hindi film directed by Raaj Shaandilyaa, grossed over $5 million globally in ten days....
By Forbes | 4 weeks ago -
IDYA Stock Price | IDEAYA Biosciences Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
IDEAYA Biosciences is a biotech company specializing in oncology precision medicine, with a focus on targeted therapeutics based on molecular diagnostics. Their product IDE196 is a kinase inhibitor fo...
By MarketWatch | 4 months ago -
IDEAYA Biosciences, Inc. (IDYA) Stock Price, News, Quote & History
IDEAYA Biosciences is a precision medicine oncology company developing targeted therapeutics for genetically defined cancers using molecular diagnostics. Their products in development include inhibito...
By Yahoo! Finance | 4 months ago
